Genmab — November 2019
-
Korrekt Helge
-
he he Helge

-
Bluebird Bio hvor en del analytikere efter ASH 2017 frygtede skulle tage en del af MM markedet med deres CAR-T produkt, har godt nok fået tæsk på det seneste. Den fløj op over 200 dengang, men har på det seneste været i konstant nedgang. I går over 6% ned til nu 72.
-
Brian Durie om bb21217: The efficacy and tolerability profiles are similar to the original bb2121. Måske derfor. bb21217 skulle jo være en klar forbedring. https://www.myeloma.org/cure-blog/ash-top-10-2019-immune-therapies-again-dominate-news
-
Kaffekoppen er stadig uden revner https://forextraininggroup.com/trading-cup-handle-pattern-best-results/
-
Genmabs partner på Tisotumab, SGEN, stiger pænt og nærmer sig $20bn i markedsværdi. Underskudsgivende indtil nu og ikke så stærk finansielt som Genmab. Man kan diskutere hvem der står stærkest med pipelinen. Men Genmab kan principielt være mindst lige så værdifuldt.
-
Genmab capital increase
-
-
due to warrent exercise of course

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind